Surrozen, Inc. (SRZN): Depreciation & Amortization
$537.0K
Year ended 2025-12-31
$222.0K
Trailing 12 months to 2026-06-30
-35.0%
3-year compound annual growth
-22.6%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $537.0K | -62.8% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $1.44M | -24.5% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $1.91M | -2.3% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $1.96M | -5.4% | 2024-04-10, From 2022-01-01 |
| 2021-12-31 | $2.07M | +6.7% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $1.94M | n/a | 2022-03-28, From 2020-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Surrozen, Inc. (SRZN) | 2025-12-31 | $537.0K | -62.8% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $19.48M | +1.1% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $1.45M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $7.32M | +19.5% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $73.0K | -1.4% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $2.99M | +9.8% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $12.90M | -32.0% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $117.1K | +2.8% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.42M | -13.8% |
Compare SRZN, CRSP, CGON, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗